Leo Pharma launches new plaque psoriasis therapy Enstilar in UK

Leo Pharma has announced the launch of Enstilar, the first fixed-combination cutaneous foam spray treatment for plaque psoriasis, in the UK.

Indicated for the once-daily topical treatment of all extents of plaque psoriasis among patients who are 18 years or older, the treatment has been shown to offer advantages over other topical therapies in clinical studies.

More than half of patients treated with Enstilar in pivotal trials experienced significant visible signs of improvement within four weeks, with some seeing improvements after only a week of treatment.

It was also shown that 81 percent of psoriasis patients using Enstilar foam spray reported quality of life improvements after four weeks, with more than 70 percent seeing a reduction in itch-related sleep loss.

Professor Chris Griffiths, foundation professor of dermatology at the University of Manchester, said: "Clinical data points to the superior efficacy of Enstilar over other topical combination therapies, and to a favourable safety profile."

The drug received regulatory approval in March this year, based on positive data from the phase IIIa trial PSO-FAST.